Factors
|
Number (%)
|
Median DFS (months)
|
P value
|
---|
Sex
|
male
|
111 (73.5)
|
33.99
|
0.036*
|
|
female
|
40 (26.5)
|
21.13
| |
Age
|
<55 years
|
74 (49.0)
|
21.45
|
0.330
|
|
≥55 years
|
77(51.0)
|
31.97
| |
Smoking status
|
no
|
65 (43.0)
|
22.24
|
0.305
|
|
yes
|
86 (57.0)
|
32.99
| |
Stage
|
I
|
54 (35.8)
|
NR#
|
0.001*
|
|
II
|
47 (31.1)
|
33.64
| |
|
III
|
50 (33.1)
|
15.18
| |
T stage
|
T1
|
38 (25.2)
|
NR#
|
0.03
|
|
T2
|
99 (65.5)
|
18.76
| |
|
T3-4
|
14 (9.3)
|
38.16
| |
N stage
|
N0
|
62 (41.1)
|
NR#
|
<0.001*
|
|
N1
|
50 (33.1)
|
33.64
| |
|
N2
|
39 (25.8)
|
13.37
| |
Histology
|
Adenocarcinoma
|
59 (39.1)
|
17.41
|
0.004*
|
|
Non- adenocarcinoma
|
92 (60.9)
|
48.16
| |
Surgery method
|
Wedge resection
|
5 (3.3)
|
17.41
|
0.958
|
|
Lobectomy
|
123 (81.5)
|
24.41
| |
|
Pneumonectomy
|
23 (15.2)
|
31.15
| |
Chemotherapy regimens
|
Docetaxel-containing
|
40 (26.5)
|
18.60
|
0.523
|
|
Vinorelbine- containing
|
40 (26.5)
|
48.16
| |
|
Gemcitabine- containing
|
51 (33.8)
|
24.58
| |
|
Paclitaxel- containing
|
20 (13.2)
|
24.41
| |
TopIIα
|
Low expression
|
117 (77.5)
|
19.38
|
0.012*
|
|
High expression
|
34 (22.5)
|
NR
| |
Ki67
|
Low expression
|
96 (63.6)
|
22.24
|
0.517
|
|
High expression
|
55 (36.4)
|
29.37
| |
- * P < 0.05 was considered statistically significant; # NR = not reached